ERBB2 and small cell lung carcinoma: As well as this mechanism, c-MET amplification (5– 10%), HER2 amplification (12%), PIK3CA mutations (5%), BRAF mutations (1%), small-cell lung cancer histological transformation (3–14%) and so on are also associated with acquired resistance to EGFR-TKIs [4].